ONE-WAYOngoing theme · still written in the latest filings
Next-Phase Clinical Development of CBP501 and Pursuit of Its First Launch
A standalone drug development program positioning CBP501 as the company’s first product to be launched, with preparations and filings underway for a U.S. Phase 2b trial and a European Phase 3 trial, aiming to obtain approval and launch the product.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.